Latest news with #VisionAI
Mint
3 days ago
- Entertainment
- Mint
10 new Samsung TVs with smart features, stunning picture quality and more for next-level entertainment
When it comes to buying a new Samsung TV, you get more than just a TV. These latest smart TVs bring innovation and smart features to everyday viewing. From crisp 4K displays to intuitive user controls, the best Samsung TV models deliver a smooth and rich experience. With support for popular apps and in-built smart features, your TV turns into an entertainment hub. You can mirror your smartphone, browse the web, or use voice assistants to manage what you watch. Product Rating Price BEST OVERALL Samsung 80 cm (32 Inches) Wondertainment Series HD Ready LED Smart TV UA32T4340BKXXL (Glossy Black) View Details VALUE FOR MONEY Samsung 108 cm (43 inches) Crystal 4K Neo Series Ultra HD Smart LED TV UA43AUE65AKXXL (Black) View Details Samsung 138 cm (55 inches) Vision AI 4K Ultra HD Smart QLED TV QA55QEF1AULXL View Details Samsung 80 cm (32 inches) HD Ready Smart LED TV UA32T4380AKXXL (Glossy Black) View Details Samsung 108 cm (43 inches) Full HD Smart LED TV UA43T5450AKXXL (Black) View Details View More The new Samsung TVs are available in various sizes, giving you flexibility to pick one based on your room. The best smart TV should offer strong performance, reliable updates, and excellent visuals, and Samsung does exactly that. The modern design and premium build quality make each model stand out. Explore Samsung's latest range if you want a reliable, feature-packed smart TV that fits beautifully into any modern home setup. Part of the best 10 New Samsung TVs, this 32-inch Wondertainment model blends compact size with smart features. It brings HD picture clarity, Dolby-enhanced sound, and direct app access via remote hotkeys. Designed for smaller spaces, it offers Samsung TV Plus, screen mirroring, and a clean interface. The glossy black finish and slim design make it a good fit for bedrooms, kitchens, or study rooms looking for a simple smart upgrade. Dimensions 73.2W x 43.9H x 8.3D cm Built-in OTT hotkeys for convenience Good sound quality with Dolby audio Limited internal storage What are buyers saying on Amazon? Buyers highlight the picture sharpness and useful OTT shortcuts in this easy-to-use smart TV. Choose this for an affordable Samsung Smart TV that's compact, stylish, and loaded with essential smart features. The Crystal 4K Neo Series 43-inch TV earns its spot among the best 10 New Samsung TVs with its rich 4K clarity and sleek design. Its Crystal Processor 4K enhances every frame, while HDR10+ support and one billion colour reproduction boost visual appeal. Built-in voice assistants and smart remote make streaming effortless, and adaptive sound optimises audio across scenes. Ideal for modern homes needing a dependable mid-size 4K smart TV. Dimensions 96.3W x 56.2H x 7.8D cm Voice assistant compatibility Adaptive audio enhances sound 50Hz panel less ideal for fast-paced gaming What are buyers saying on Amazon? Buyers like this TV for its sharp display, modern design, and ease of streaming OTT apps. Pick this for brilliant 4K visuals, voice control, and a smooth smart TV experience in a compact size. For those seeking a high-end cinematic experience at home, this Vision AI model ranks among the best 10 New Samsung TVs. The 55-inch QLED panel delivers vivid detail and enhanced brightness. Backed by the Q4 AI Processor, it offers 4K upscaling, object-tracking sound, and rich colour volume with Quantum Dot tech. With multi-view, smart mirroring, and Matter/SmartThings integration, it becomes the centrepiece of any smart home setup. Dimensions 123.4W x 75.8H x 23.7D cm Built-in AI upscaling Feature-rich display modes Moderate refresh rate What are buyers saying on Amazon? Buyers prefer this QLED for its premium feel, colour richness, and compatibility with smart home devices. Select this for immersive QLED visuals, smart features, and a living room upgrade that feels premium. A solid entry in the list of best Samsung TVs under 32 inches, this model focuses on functionality and ease of use. It delivers HD visuals with vivid colour contrast and Dolby audio for better sound output. Built-in apps, screen sharing, and support for popular OTT platforms make it a practical option for compact spaces. A reliable choice for students, guest rooms, or casual streaming setups. Dimensions 72.3W x 72.3H x 8.6D cm Simple and easy interface Dolby audio for better clarity Limited app support What are buyers saying on Amazon? Buyers highlight the value for money, user-friendly setup, and suitable size for compact rooms. Opt for this for basic smart TV functions and compact HD entertainment on a budget. Positioned between HD and 4K, this model stands out among the best 10 New Samsung TVs offering Full HD clarity. The Hyper Real Engine enhances colour and contrast, while Dolby Digital sound and multiroom linking improve audio depth. SmartThings support, game mode, and screen mirroring add flexibility. Perfect for users who want a bigger screen without stepping into the 4K price bracket. Dimensions 96.3W x 56.2H x 7.8D cm Crisp Full HD output Smooth upscaling and colour 50Hz refresh rate What are buyers saying on Amazon? Buyers like the picture sharpness and balanced performance of this mid-range Samsung smart TV. Pick this for Full HD entertainment with smart features and balanced audio-video quality. The D Series Crystal 4K Vivid Pro enhances your viewing experience with vibrant images and a sharp Ultra HD display. Its Crystal Processor ensures smoother 4K upscaling and visual clarity. With Q‑Symphony sound, SmartThings Hub, and Apple AirPlay support, it fits effortlessly into a connected lifestyle. A great pick from the best Samsung TVs for modern households focused on vivid visuals and smart utility. Dimensions 96.8W x 56.1H x 6D cm Brilliant 4K quality Smooth connectivity Limited storage What are buyers saying on Amazon? Buyers like the colour punch and quick navigation, calling it a value-packed 4K TV. Select this for sharp 4K visuals, Q‑Symphony sound, and a connected smart home experience. Offering a sleek design and future-ready features, this model stands out in the list of best 10 New Samsung TVs. Its Crystal Processor 4K ensures vibrant colour and sharp upscaling. Built-in Alexa, Samsung Knox Security, and SolarCell remote add value and convenience. The slim bezel design and smart integration make it ideal for stylish, connected homes looking for more than just a display. Dimensions 96.8W x 56.1H x 6D cm Built-in voice assistant Secure with Samsung Knox Lower energy rating What are buyers saying on Amazon? Buyers prefer the voice assistant features and sleek design, calling it a modern smart TV for smart homes. Choose this for sleek aesthetics, built-in Alexa, and vibrant 4K viewing with strong privacy support. Striking a great balance between size and performance, this 50-inch Crystal 4K model is a worthy pick from the best Samsung TVs. Its PurColor and HDR10+ capabilities deliver lifelike visuals, while the Object Tracking Sound adds depth to audio. Designed for immersive viewing, it offers seamless smart features like Multi View, SmartThings support, and a slim bezel-free look. Dimensions 112W x 69.4H x 23.7D cm Bezel-less sleek design Great display-to-sound match No Dolby Vision Slightly bulky base stand What are buyers saying on Amazon? Buyers like this for its immersive sound and brilliant picture, calling it a complete mid-size smart TV. Pick this for a solid 50-inch 4K screen with crisp sound and smart connectivity for modern families. Built for cinematic viewing, this 65-inch giant from Samsung's D Series is perfect for large living spaces. With a powerful Crystal Processor 4K, UHD Dimming, and Motion Xcelerator, it ranks among the best 10 New Samsung TVs for premium clarity. Its support for SmartThings, IoT devices, and Apple AirPlay makes it more than just a TV — it's a smart entertainment hub. Dimensions 145.3W x 83.4H x 6.1D cm Perfect for large rooms Smooth 4K upscaling No voice control remote What are buyers saying on Amazon? Buyers like this for its large screen, rich display colours, and smart compatibility across devices. Opt for this for a massive screen, smooth visuals, and smart home integration in one solid package. The biggest in this list of best Samsung TVs, this 75-inch model is built for theatre-like experiences at home. Featuring Motion Xcelerator, UHD Dimming, and Object Tracking Sound, every scene becomes immersive. It supports Samsung TV Plus, Apple AirPlay, Alexa, and IoT sensors, making it a smart centrepiece for large modern homes. The 3-side bezel-less design enhances wall presence without compromising style. Dimensions 167.8W x 96.2H x 6.1D cm Huge screen with clear motion Full smart feature suite Not suitable for small spaces What are buyers saying on Amazon? Buyers highlight the cinematic effect, sound quality, and advanced features that turn any room into a theatre. Choose this for theatre-size visuals, smart connectivity, and immersive sound in a strikingly large design. The latest Samsung Crystal 4K TVs use Crystal Processor 4K for sharper visuals, 4K upscaling, and vivid colour reproduction. With features like HDR10+, Adaptive Sound, and sleek bezels, they offer an immersive experience ideal for both content lovers and modern households with smart connectivity needs. Most of the new Samsung TVs support voice assistants like Alexa and Bixby. Higher-end models come with built-in voice control and a smart remote. Some entry-level models may require external smart speakers for full voice assistant integration. What apps are supported on these new Samsung Smart TVs? All models support major OTT platforms like Netflix, Prime Video, YouTube, Hotstar, Zee5, and more. Samsung's own TV Plus offers 100+ free live channels. The Tizen operating system ensures a smooth app experience with updates and a user-friendly interface. Resolution : Choose between HD Ready, Full HD, or 4K depending on your needs. : Choose between HD Ready, Full HD, or 4K depending on your needs. Screen Size : Ensure the TV fits your space and provides comfortable viewing distance. : Ensure the TV fits your space and provides comfortable viewing distance. Display Technology : Opt for QLED for richer colours and contrast or Crystal UHD for value. : Opt for QLED for richer colours and contrast or Crystal UHD for value. Smart Features : Look for Tizen OS, OTT app support, voice assistant compatibility, and screen mirroring. : Look for Tizen OS, OTT app support, voice assistant compatibility, and screen mirroring. Audio Quality : Check for Dolby Digital Plus, Q-Symphony, and Object Tracking Sound if sound quality matters. : Check for Dolby Digital Plus, Q-Symphony, and Object Tracking Sound if sound quality matters. Connectivity Ports : Ensure enough HDMI and USB ports for your external devices. : Ensure enough HDMI and USB ports for your external devices. Build & Design : Consider slim bezels, table stand options, and wall-mount readiness. : Consider slim bezels, table stand options, and wall-mount readiness. Remote Features : Premium models offer SolarCell and voice-enabled remotes. : Premium models offer SolarCell and voice-enabled remotes. Smart Home Compatibility: Look for SmartThings or Matter Hub support for IoT control. Top 3 features of the 10 new Samsung TV: Best Samsung TV Display Connectivity Special Features LED Wi-Fi, USB, Ethernet, HDMI HD Picture Quality , HotKeys for quick access of OTT App LED Wi-Fi, USB, Ethernet, HDMI Voice Assistants, Smart Remote, Universal Guide QLED Wi-Fi, USB, Ethernet, HDMI 100% Color Volume with Quantum Dot LED Wi-Fi, USB, Ethernet, HDMI Screen Share , Music System, Content Guide LED, FHD, Hyper Real Picture Engine Wi-Fi, RF, USB, Ethernet, HDMI UHD Wi-Fi, USB, Ethernet, HDMI Crystal Processor 4K, 4K Upscaling LED Wi-Fi, USB, Ethernet, HDMI Samsung Knox Security , Endless Free Content , SolarCell Remote LED Wi-Fi, USB, Ethernet, HDMI Samsung Knox Security , Endless Free Content , 4K Upscaling UHD Wi-Fi, USB, Ethernet, HDMI UHD Dimming, Motion Xcelerator UltraHD Wi-Fi, USB, Ethernet, HDMI Crystal Processor 4K, 4K Upscaling, UHD Dimming Disclaimer: Mint has an affiliate marketing partnership, which means we may get some commission on purchases you make through the retailer sites links provided. These partnerships do not influence our editorial content, which is free from any bias or marketing pitch. We strive to provide accurate and unbiased information to help you make informed decisions. We recommend verifying details with the retailer before making a purchase.
Cision Canada
5 days ago
- Business
- Cision Canada
AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 30, 2025 /CNW/ -- Several experts are seeing that value of AI's total overhaul of healthcare, including beneficial additions such as generative AI apps demonstrating real value. The next wave of AI's healthcare transformation is already taking shape—led by intelligent agents, next-gen diagnostics, and predictive drug discovery platforms. Behind the scenes, a new class of innovators is making tangible progress, with companies like Avant Technologies, Inc. (OTCQB: AVAI), Tempus Ai, Inc. (NASDAQ: TEM), OmniAb, Inc. (NASDAQ: OABI), Tevogen Bio Holdings Inc. (NASDAQ: TVGN), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). ResearchAndMarkets projects the AI medical diagnostics market to surge to $46.59 billion by 2034, driven by a blistering 33.72% CAGR. Private equity firms believe 2025 could eclipse 2024 as the biggest year yet for AI-powered health tech. Recent raises include $300 million for Abridge (AI medical transcription), $101 million for Tennr (automated patient referrals), and $45 million for Ellipsis Health, which is developing emotionally intelligent AI for mental health. Meanwhile, in the public markets, several companies are moving beyond hype with real-world AI deployments already underway. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech are preparing for a pivotal milestone: their pre-submission meeting with the U.S. FDA, scheduled for July 7. This session will shape the clinical pathway for Vision AI, the companies' flagship disease-screening platform, as they seek 510(k) clearance for U.S. marketing approval—a move that could unlock major commercial potential. With experienced regulatory advisors and a global CRO, Fortrea, assisting in final preparations, the team is aiming for an efficient regulatory process that leads to large-scale diabetic screening capabilities across the U.S. "We're approaching a key milestone," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio. "We've been preparing thoroughly with the support of an experienced CRO and expert regulatory advisors, and we're optimistic about the outcome. Diabetic retinopathy is the number one cause of preventable blindness worldwide. That's unacceptable—and we believe technology can change that. But this is just the beginning. Retinal screening offers a gateway to detecting many systemic conditions early—like Alzheimer's, cardiovascular disease, and more." Avant's broader diabetes push is now entering a critical phase. It has signaled intentions to launch a standalone company to develop a potential treatment for diabetes, complementing its screening and detection suite. This would streamline its structure by integrating data, IP, and leadership under one roof, eliminating the holding-company inefficiencies currently in place. Over 30% of those living with diabetes will develop diabetic retinopathy, a disease that can be prevented with an accurate diagnosis. More recently, Avant and joint-venture partner Ainnova Tech have begun offering free Vision AI scans inside Grupo Dökka's Fischel and La Bomba pharmacy chains. Avant's Vision AI platform uses retinal imaging and artificial intelligence to rapidly detect diabetic retinopathy and other retinal diseases, as well as systemic conditions like fatty liver, chronic kidney disease, and cardiovascular risk. The team is finalizing a low-cost, cloud-connected retinal camera that could operate in clinics and rural settings without specialist staff. And with new disease modules in the pipeline—including a blood test-linked dementia screening tool— Avant is steadily building out a scalable, multi-condition platform designed to close the loop between early detection and timely intervention. "We're committed to pushing the boundaries of preventive care, improving both life expectancy and quality of life for people around the world," added Vargas. "That's the mission behind everything we do." Recently, Avant signed a non-binding letter of intent to acquire 100% of Ainnova Tech —bringing leadership, data, and intellectual property together ahead of a scheduled FDA pre-submission meeting in July. Folding the joint venture into a single public entity would remove the current holding-company structure, streamlining everything from regulatory filings to revenue recognition. Tempus Ai, Inc. (NASDAQ: TEM) is expanding its clinical impact through the validated performance of the CARE Program, a digital health platform from its subsidiary Ambry Genetics. Published data shows the tool identifies hereditary cancer risk with 99.5% accuracy by interpreting NCCN Guidelines—simplifying complex decision-making for non-specialist clinicians. "CARE offers healthcare systems a quality, end-to-end solution that transforms how they identify the need for, implement, and scale genetic testing," said Tom Schoenherr, CEO of Ambry Genetics. "Because clinicians can trust CARE's comprehensive history collection and accurate risk assessment, they can feel confident expanding access to genetic services, improving outcomes for more patients, and making genetic testing a seamless part of their patient care and population health strategies." The system integrates directly with EHRs and collects patient histories via mobile devices, flagging those eligible for further genetic testing or enhanced screening. This marks another step forward in Tempus' mission to make AI-powered precision medicine more accessible, scalable, and proactive. OmniAb, Inc. (NASDAQ: OABI) unveiled new case studies demonstrating the power of its xPloration® platform—an AI-driven, high-throughput B-cell screening system that accelerates therapeutic antibody discovery. "Thorough mining of primary B-cells from immunized animals presents a major challenge in therapeutic antibody discovery," said Dr. Bob Chen, Ph.D., Vice President, Discovery Systems, who gave the presentation, titled xPloration: Simplifying Deep Antibody Mining for Maximum Impact. "Traditional methods often restrict antibody diversity and require weeks to complete. In contrast, the xPloration platform processes millions of single B-cells and recovers thousands of antibody variants within hours, achieving impactful results." The platform boosts both speed and diversity, giving partners a powerful edge in mining immune repertoires, and boosts the effectiveness of discovery programs by screening 10 times more single cells per day than other spatial separation techniques. Tevogen Bio Holdings Inc. (NASDAQ: TVGN) is advancing development of an EBV-specific T cell therapy using its proprietary ExacTcell™ platform, with AI playing a central role in target selection. "The mechanisms behind EBV-induced tumorigenesis, which includes the disruption of cellular pathways and the promotion of malignant growth by EBV proteins, have become increasingly clear in recent years," said Neal Flomenberg, MD, Chief Scientific Officer of Tevogen Bio. "Targeting these proteins with highly specific CTLs presents an exciting research frontier and the potential for meaningful therapeutic breakthroughs in EBV-driven cancers." The company's internal AI division, is helping identify immunologically active peptides across the Epstein-Barr virus genome to guide cytotoxic T lymphocyte development. This program could open the door to a new class of precision-engineered cell therapies for virus-induced cancers. Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) and MIT have open-sourced Boltz-2, a next-generation biomolecular AI model that predicts both structure and binding affinity with unprecedented accuracy and speed. Trained on Recursion's NVIDIA -powered BioHive-2 supercomputer, Boltz-2 delivers near–free energy perturbation accuracy—at 1000x faster speeds—making it a breakthrough in AI-enabled drug discovery. "Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail," said Najat Khan, Chief R&D Officer and Chief Commercial Officer at Recursion. "Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients." The platform could drastically reduce time and cost barriers in virtual screening workflows across pharma and biotech. CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Cision Canada
5 days ago
- Business
- Cision Canada
Avant Technologies and JV Partner, Ainnova, Prepare for Key FDA Milestone with Next Week's Pre-Submission Meeting
LAS VEGAS, June 30, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that Ainnova and its Contract Research Organization, Fortrea, will use this week to make final preparations for the company's pre-submission meeting with the U.S. Food and Drug Administration (FDA) next week. The pre-submission meeting with Ainnova's executives and its CRO is set for Monday, July 7. The FDA meeting will allow the Company to discuss its planned clinical trial of Ainnova's Vision AI platform in the early detection of diabetic retinopathy. These meetings will give the team the direction it needs for a successful clinical trial and to support the Company's FDA 510(k) submission to obtain clearance from the FDA to market the Vision AI technology in the United States. Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, said, "We're approaching a key milestone. We've been preparing thoroughly with the support of an experienced CRO and expert regulatory advisors, and we're optimistic about the outcome. "Diabetic retinopathy is the number one cause of preventable blindness worldwide. That's unacceptable—and we believe technology can change that. But this is just the beginning. Retinal screening offers a gateway to detecting many systemic conditions early—like Alzheimer's, cardiovascular disease, and more. "We're committed to pushing the boundaries of preventive care, improving both life expectancy and quality of life for people around the world. That's the mission behind everything we do." Ainnova will use this pre-submission meeting to determine a host of items, including the ideal number of clinical sites, the number of total patients needed, and to learn if the FDA will approve the clinical trial protocol for the planned trial. These are all crucial for both Avant and Ainnova in determining the exact costs and a timetable. AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's interactions with the FDA are paramount to marketing the technology portfolio in the United States. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product. About Ainnova Tech, Inc. Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies Inc. is an emerging technology company developing solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is possible in AI and biotechnology, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Mint
26-06-2025
- Mint
Next generation of smart TVs: Beyond streaming to connected living
Once a humble appliance, TV is no longer just a screen for your binge-watching habits. Smart TVs are evolving into intelligent, multi-functional hubs designed to do a lot more than play Netflix. With AI smarts, cinematic displays, and deep smart home integration, the next wave of televisions is quietly turning into the centrepiece of connected living. Screens are getting massive, 100-inches isn't out of the ordinary anymore. And the visuals are jaw-dropping. We're talking 8K resolution, OLED brilliance, and Mini LED contrast that brings out rich detail in everything from cricket matches to console games. Refresh rates are also climbing, with high-end models now hitting 165Hz, giving gamers and sports fans smoother motion like never before. What's powering all this magic behind the scenes? AI. Take Samsung's Vision AI, for example: it uses neural networks to reduce glare, adjust HDR tone mapping, and even upscale HD or 4K content to near-8K clarity. So even if your content library hasn't caught up, your TV makes it feel like it has. You are no more just watching a smart TV, you are teaching it. Thanks to built-in voice recognition and usage patterns, your TV can now serve up content suggestions tailored to individual users in the household. It even knows whose voice is speaking and adapts the home screen accordingly. The remotes have also levelled up. Think fewer buttons and more control, gesture navigation, voice commands, and even integration with your Galaxy Watch to control volume or navigate menus. Your TV also talks to your lights, your air conditioner, even your pet monitor. Yes, that's a thing now. Lifestyle TVs like The Frame are making waves too, turning your television into a gallery when not in use. Eco-conscious? Many new models now feature selective LED illumination that cuts power consumption by 30%, without sacrificing brightness. Brands like Samsung, LG, and TCL are going all-in on larger, AI-infused models, and consumer interest is clearly shifting toward these premium offerings. The only friction points? Content availability in 8K and the premium price tag, which still keeps some models out of reach for the average buyer. The smart TV isn't just surviving, it's thriving. As AI gets smarter and displays get more immersive, your next television could become the nerve centre of your home. It can be running your entertainment, syncing your devices, and responding to your life without you lifting a finger.
Cision Canada
24-06-2025
- Business
- Cision Canada
New AI Rollouts Signal Shift From Hype to Healthcare Reality
VANCOUVER, BC, June 24, 2025 /CNW/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is being developed by innovators who have been making serious progress for AI in healthcare, including updates from Avant Technologies, Inc. (OTCQB: AVAI), Eli Lilly and Company (NYSE: LLY), Palantir Technologies Inc. (NASDAQ: PLTR), Koninklijke Philips N.V. (NYSE: PHG), and Waystar Holding Corp. (NASDAQ: WAY). According to private equity investors, this year could be even bigger than 2024 for health technology companies. Recent private raises include $101 million for Tennr, $45 million for Ellipsis Health and $28 million for Autonomize AI. In the public markets, there are several opportunities that involve actual rollouts of AI healthcare tech in practice. Avant Technologies, Inc. (OTCQB: AVAI) just signaled its biggest move yet: the creation of a new company dedicated to developing a potential treatment for diabetes. According to their latest update, Avant is set to launch either a joint venture, partnership, or an acquisition to accomplish this intention as it expands its interests in diabetes, which impacts over 500 million people globally. Avant's flagship Vision AI tech is designed to detect the early markers of diseases like diabetic retinopathy, which is the leading cause of blindness among working age adults. Vision AI is a cutting-edge, AI-driven platform that can detect diabetic retinopathy and other retinal diseases with high accuracy and speed using retinal scans, as well as diseases unrelated to the retina like cardiovascular disease, prediabetes and type 2 diabetes, fatty liver diseases, and chronic kidney disease. "It is the work we're doing with Ainnova to screen diabetes patients to identify the early signs of diabetic retinopathy that is driving Avant to contribute even more to the fast-growing disease—a potential treatment," said Chris Winter, CEO of Avant Technologies. "We are exploring several promising opportunities to get involved in the development of a treatment for diabetes globally, and if successful, we want to be ready to hit the ground running with the formation of a company to house that opportunity." Over 30% of those living with diabetes will develop diabetic retinopathy, a disease that can be prevented with an accurate diagnosis. More recently, Avant and joint-venture partner Ainnova Tech have begun offering free Vision AI scans inside Grupo Dökka's Fischel and La Bomba pharmacy chains. "As we begin similar initiatives in Mexico, our goal is to close the patient care loop with timely treatment, connecting every step of the journey," said Vinicio Vargas, CEO of Ainnova Tech and board member of Ai-nova Acquisition Corp. "We are integrating pharma, retail, ophthalmologists, and our technology into a unified experience, all driven by one incentive, the well-being of the diabetic patient." Back in late 2024, Avant entered into the joint venture with Ainnova Tech to form Ai-nova Acquisition Corp (AAC) to advance and commercialize Ainnova's technology portfolio, including the Vision AI platform, and its versatile retinal cameras. Avant now expects that a new relationship will allow it to expand its diabetes program to both identify the early markers of the disease and to treat diabetes. Recently, Avant signed a non-binding letter of intent to acquire 100% of Ainnova Tech —bringing leadership, data, and intellectual property together ahead of a scheduled FDA pre-submission meeting in July. Folding the joint venture into a single public entity would remove the current holding-company structure, streamlining everything from regulatory filings to revenue recognition. Management sees the unified cap table as a potential draw for both investors and strategic partners. While the legal teams work through due diligence, engineers are finalizing a low-cost, automated retinal camera built to work seamlessly with the Vision AI platform. Legacy fundus cameras can run into the tens of thousands and typically require skilled operators. Avant's prototype is fully automated, cloud-connected, and designed for a fraction of the cost. If performance holds up to internal testing, the system could enable large-scale diabetic screenings in clinics and low-resource settings—without the need for additional specialist staff. Vision AI is also expanding beyond diabetic eye disease. A patented dementia-risk module —pairing a five-minute blood test with AI pattern recognition—is now in validation, while cardiovascular-risk analytics are advancing through pilot studies across Latin America. Because every new use case plugs into the same software backbone, Avant looks more like a scalable platform than a single-product company. Eli Lilly and Company (NYSE: LLY) has welcomed RyboDyn into its Lilly Gateway Labs program in San Diego as part of its Catalyze360™ model for accelerating biotech innovation. The move supports development of RyboDyn's AI-powered immunotherapies targeting the "dark proteome," a novel set of cancer-specific markers absent in healthy tissues. "We're thrilled to join the LGL community and collaborate with peers who share our urgency to translate high-impact science," said Imad Ajjawi, PhD, MBA, CEO and Co-founder of RyboDyn. " Lilly's support comes at a pivotal moment as we advance our first wave of programs toward therapeutic development." Backed by early results from Moffitt Cancer Center, the company is now advancing these targets toward first-in-human studies. Palantir Technologies Inc. (NASDAQ: PLTR) has entered a strategic partnership with TeleTracking to improve hospital operations using AI-driven insights. The collaboration integrates Palantir's Foundry and AIP platforms with TeleTracking's Operations IQ to optimize staffing, capacity, and patient flow across healthcare systems. "This partnership with TeleTracking represents the AI revolution in healthcare we are in the midst of-where we continue to move closer to a world where all hospitals and health systems are embracing, implementing and operating with an AI-powered approach, helping to streamline operations allowing for increased focus on providing the best level of care," said Alex Karp, CEO at Palantir. The joint solution delivers near real-time situational awareness to reduce caregiver burden and improve outcomes. Koninklijke Philips N.V. (NYSE: PHG) has published new APAC data from its Future Health Index 2025, spotlighting the region's critical care delays and strained health systems. Two-thirds of patients are facing average wait times of 47 days for specialist access, with 33% reporting worsened health outcomes as a result. Meanwhile, 89% of healthcare professionals surveyed believe AI can save lives through faster interventions, while 76% report losing time due to incomplete patient data. "The need for AI has never been greater. Our survey shows that patients are anxiously waiting more than a month for specialist care, while some healthcare professionals are losing about four working weeks of clinical time a year due to incomplete patient data," said Jasper Westerink, Senior Vice President and Representative Director of Philips Japan and Acting Managing Director of Philips APAC. "There is a clear role for AI to help clinicians act faster, make better decisions, and anticipate patient needs earlier as we strive to deliver better care for more people." These findings underscore a growing consensus that AI adoption is no longer optional but essential for long-term care delivery improvements across Asia Pacific. Waystar Holding Corp. (NASDAQ: WAY) has published new research showing that artificial intelligence is now a mission-critical component of revenue cycle management for healthcare providers. "This research reinforces what we're seeing across the industry. AI is no longer theoretical and is fundamentally reshaping how providers operate," said Matt Hawkins, CEO of Waystar. "As healthcare organizations navigate growing complexity, the study shows they're relying on proven and trusted RCM software providers to deploy AI." According to the Forrester Consulting study, AI is delivering 13–37% gains in areas like claim accuracy, payment speed, and workforce efficiency. With 82% of healthcare leaders calling AI essential to their operations, the report marks a clear inflection point in healthcare's digital transformation. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
